Close Menu

NEW YORK – OpGen said on Wednesday that its subsidiary Curetis has received more than €350,000 ($410,000) from the Federal German Ministry of Education and Research to use artificial intelligence for developing a test for carbapenem resistance in Gram-negative bacteria.

The project includes Curetis, based in Holzgerlingen, Germany, and collaborators at the Research Campus InfectoGnostics and is coordinated by Jena University Hospital. Curetis alone received €350,000 for the project, which is expected to start this month and run until August 2025.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.